Company Overview

Neurogene Inc. (Nasdaq: NGNE) is a clinical-stage biotechnology company focused on developing genetic medicines for rare neurological diseases. The company operates within the biotechnology and gene therapy industries, with a primary emphasis on adeno-associated virus (AAV)-based therapies and gene regulation technologies intended to address disorders of the central nervous system. Neurogene’s core objective is to develop treatments for severe pediatric neurological conditions with high unmet medical need, particularly diseases caused by single-gene mutations.

The company’s primary revenue and value drivers are its proprietary therapeutic candidates and platform technologies rather than commercial product sales, as Neurogene remains in the clinical development stage. Its lead programs include therapies targeting Rett syndrome and other rare neurodevelopmental disorders. A key differentiator for Neurogene is its development of regulated gene therapy approaches designed to control protein expression levels, an important consideration in diseases where overexpression may create safety risks. Neurogene was founded in 2018 and expanded its capabilities through internal research efforts and strategic acquisitions, including the acquisition of Neoleukin Therapeutics, which broadened aspects of its technology and public-market infrastructure.

Business Operations

Neurogene organizes its operations around research, development, and advancement of genetic medicines targeting rare neurological disorders. The company’s principal business activities include preclinical research, clinical development, manufacturing coordination, regulatory engagement, and intellectual property development. Its lead therapeutic programs have included candidates for Rett syndrome and related neurological diseases, supported by its proprietary EXACT™ gene regulation technology platform intended to enable more precise control of therapeutic gene expression.

The company operates primarily in the United States, with research and corporate activities centered domestically while engaging international clinical sites, manufacturing partners, and scientific collaborators where appropriate. Neurogene relies on specialized contract development and manufacturing organizations for portions of vector manufacturing and clinical supply production. The company also maintains relationships with academic institutions, clinical investigators, and rare disease advocacy groups that support clinical research and patient engagement efforts. Its operational model is characteristic of clinical-stage biotechnology companies that prioritize platform development and pipeline advancement over near-term commercial operations.

Strategic Position & Investments

Neurogene’s strategic direction centers on advancing differentiated genetic medicines for severe neurological disorders where current treatment options are limited or nonexistent. A major focus has been the advancement of regulated gene therapy approaches intended to improve dosing precision and safety in disorders involving dosage-sensitive genes. The company has emphasized the development of therapies capable of addressing complex neurological conditions through targeted central nervous system delivery and controlled transgene expression.

The acquisition of Neoleukin Therapeutics represented a notable corporate transaction that supported Neurogene’s evolution as a publicly traded biotechnology company and provided additional financial and operational flexibility. Neurogene continues to invest in clinical development, manufacturing readiness, regulatory strategy, and expansion of its intellectual property portfolio. The company’s technology development efforts place it within broader emerging sectors of precision genetic medicine, AAV-based therapeutics, and next-generation gene regulation systems for rare diseases.

Geographic Footprint

Neurogene is headquartered in New York, United States, and conducts the majority of its corporate, research, and development activities within the U.S. The company’s operational footprint is primarily concentrated in North America, although its clinical development and manufacturing activities involve partnerships and vendors that may extend into Europe and other international regions commonly involved in biotechnology research and pharmaceutical supply chains.

While Neurogene does not currently maintain the broad commercial infrastructure of a multinational pharmaceutical company, it participates in globally interconnected biotechnology networks through clinical collaborations, regulatory engagement, manufacturing relationships, and scientific partnerships. Its target patient populations for rare neurological diseases are globally distributed, creating potential future international relevance if its therapeutic candidates achieve regulatory approval.

Leadership & Governance

Neurogene’s leadership team includes executives with backgrounds in biotechnology, rare disease drug development, neuroscience, and genetic medicine commercialization. The company’s governance structure reflects a clinical-stage biotechnology focus, emphasizing scientific innovation, regulatory execution, and capital allocation to support long-term pipeline development. Public communications and corporate strategy have consistently emphasized advancing potentially transformative therapies for severe neurological disorders while maintaining disciplined clinical and operational execution.

Key executives include:

• Rachel McMinn – Founder, President, and Chief Executive Officer
• Matthew During – Founder and Chief Scientific Advisor
• Eric David – Chief Financial Officer
• Arthur Tzianabos – Chief Medical Officer
• Nuria Pascual – Chief Technical Officer

The company’s leadership philosophy has emphasized patient-focused development, scientific rigor, and the pursuit of differentiated gene therapy technologies designed to improve safety and therapeutic precision in neurological disease treatment.